GlaxoSmithKline has become the first FTSE 100 company to offer employees a group option for self invested personal pensions (Sipps) – a move likely to be followed by many other big blue-chips.

The pharmaceutical giant’s decision gives workers the chance to invest their pension pot in a wide variety of assets ranging from commercial property and overseas shares to more exotic classes such as listed hedge funds.